Your browser doesn't support javascript.
loading
International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.
Trappe, R U; Choquet, S; Dierickx, D; Mollee, P; Zaucha, J M; Dreyling, M H; Dührsen, U; Tarella, C; Shpilberg, O; Sender, M; Salles, G; Morschhauser, F; Jaccard, A; Lamy, T; Reinke, P; Neuhaus, R; Lehmkuhl, H; Horst, H A; Leithäuser, M; Schlattmann, P; Anagnostopoulos, I; Raphael, M; Riess, H; Leblond, V; Oertel, S.
Affiliation
  • Trappe RU; Department of Internal Medicine II: Hematology and Oncology, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Hematology, Oncology and Tumor Immunology Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany.
Am J Transplant ; 15(4): 1091-100, 2015 Apr.
Article in En | MEDLINE | ID: mdl-25736912
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B-Lymphocytes / Antigens, CD20 / Rituximab / Lymphoproliferative Disorders Type of study: Prognostic_studies Limits: Humans / Middle aged Language: En Journal: Am J Transplant Journal subject: TRANSPLANTE Year: 2015 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: B-Lymphocytes / Antigens, CD20 / Rituximab / Lymphoproliferative Disorders Type of study: Prognostic_studies Limits: Humans / Middle aged Language: En Journal: Am J Transplant Journal subject: TRANSPLANTE Year: 2015 Document type: Article Affiliation country: Country of publication: